The Correlation Analyses of Parkinson’s Disease with Serum Homocysteine, Folic Acid and Vitamin B12
Objective: To explore the associations of serum homocysteine (Hcy), folic acid (FA) and vitamin B12 (VitB12) levels with the severity of Parkinson's disease (PD), as…Serum Metabolomic Characterization of PLA2G6-associated Dystonia-Parkinsonism: a case-control biomarker study
Objective: PLA2G6 is the causative gene for autosomal recessive Dystonia-Parkinsonism (PARK14). This case-control biomarker study aimed to test serum metabolomics of patients diagnosed as PARK14.…α-Synuclein molecular behavior and proteomic profiling distinguish subtypes of Lewy body disorders
Objective: We hypothesized that the clinical heterogeneity found in Lewy body disorders is a consequence of the molecular diversity of αSyn between different patients as…PLA2G6-Associated Neurodegeneration: A Continuum of Phenotypes
Objective: To characterize the spectrum of phenotypes of PLA2G6-associated neurodegeneration in a single patient. Background: The phospholipase A2 Group VI (PLA2G6) gene encodes a cytosolic and…Close relationship between CSF lipidomic alterations and cognitive decline in Parkinson’s disease.
Objective: To clarify what the lipidome of biological samples reflects in the pathology of Parkinson’s disease (PD). Background: The lipid pattern in the cerebrospinal fluid…Lipid metabolism alterations in the lysosomal membrane promotes chaperone-mediated autophagy dysfunction and alpha-synuclein pathology in Parkinson’s disease associated to GBA
Objective: The objective of this study was to generate and characterize a new in vitro neuronal model of Parkinson's diseases associated to GBA (PD-GBA) that…Ultrastructural Characterization of Monocytes in Parkinson’s Disease and GBA mutations
Objective: To identify morphological changes in circulating CD14+ monocytes in manifesting and non-manifesting carriers of mutations of the GBA gene and Parkinson’s disease (PD). Background: Mutations of…Effect of Venglustat by GBA Mutation Severity in Patients With Parkinson’s Disease
Objective: Report outcomes from Part 2 of the phase 2 MOVES-PD trial (NCT02906020) in patients with PD stratified by glucocerebrosidase (GBA) gene mutation severity. Background:…Sensitive biomarker of Parkinson’s disease linked to mutations in the glucocerebrosidase gene
Objective: To find a biomarker for development of Parkinson’s disease (PD) in carriers of mutations in the glucocerebrosidase gene (GBA). Background: Mutations in the GBA…Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics
Objective: Describe the study design of Part 2 of the MOVES-PD trial (NCT02906020), and report patient characteristics. Background: Mutations in the glucocerebrosidase (GBA) gene are…